London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
There is obviously positivity from LTH as they know what is coming and don’t really care when! This will fluctuate as the MM’s know it is a safe bet. They can drive it up and down easily and if they are in when news arrive, they know they will multibag! Win win! I also find it irritating when MM’s manage to get in the 5’s But, I have averaged down over the last year and I am happy with my holding, even though it is higher than the 5’s.... Just! Forget the peaks and troughs if you can and wait for the end game:)
no disrespect Barwickman; but coming from the king of pointless posters, that's pretty rich. Who made you the msg board police? Everyone here is entitled to their own views, including you. All you seem to be doing the last few days is slating others for expressing theirs.
Thanks Yorkshireboy. Informative and that is what is great about this company. Truly, life-changing drugs that are quick to clinic, and commercially significant. That's why they are in advanced talks and why when the deal happens this will fly.
Continued Although, if its lack of confidence due to the fluctuating SP, I suggest the following: - ‘Things Can Only Get Better’ https://www.youtube.com/watch?v=7W3yz6abJkU Please DYOR and enjoy the sing along. Good Luck
I just thought I would remind investors why the appointment of Dr Muhunthan Thillai to Nuformix's Scientific Advisory Board was a prodigious achievement. At the time NFX stated: - ‘The appointment reflects progress made with Nuformix's NXP002 programme as a treatment for Idiopathic Lung Fibrosis (IPF) as it finalises its clinical development plans.
Muhunthan stated: - "It is a pleasure to be joining the Nuformix team at this point. The data generated to date in human IPF tissue slices versus current therapies demonstrates real promise in preventing disease progression and extending life free from side effects. Current therapies lack meaningful efficacy and their side effects can be so severe that some patients elect to stop treatment. Nuformix's approach offers the potential to move rapidly into clinic and allows us to explore other unmet needs in interstitial lung disease together." Dan stated: - ‘His in-depth understanding of patients' needs, and the short-comings of existing therapies will enable Nuformix to identify how our NXP002 programme can offer greatest benefit for his patients. Muhunthan has already contributed to numerous IPF clinical studies and is currently developing new technologies and novel imaging biomarkers that improve assessment of disease progression. On top of this, he is highly respected by his peers and well connected with the major academic and pharmaceutical players in IPF.’ RNS Number: 4774L Nuformix PLC 06 September 2019.
In addition to Mars1 excellent post, I just thought I’d add the following morsel: - Dr Muhunthan Thillai is one of 2 Directors of ‘Qureight Ltd’ which was founded in 2018 by 2 Cambridge doctors. Their platform enables analysis of images and data from multiple sources to better model diseases and assist with clinical trial endpoints. Recently, their company has made it onto the respected 2020 Confinitive: - #21toWatch, shortlist. https://www.cofinitive.com/21towatch/ Out of hundreds of entries received, 246 qualified candidates made it onto a longlist, which has now been whittled down to a shortlist of 56, featuring a dynamic mix of people, companies and ‘things’. https://www.cambridgeindependent.co.uk/business/21towatch-shortlist-of-people-companies-and-things-revealed-9099373/ The #21toWatch list will be divided into innovative and trailblazing people, companies and ‘things’ that are en route to being industry game-changers locally, nationally and globally. https://www.cofinitive.com/21towatch/companies/
Since being invested, I have always had the greatest respect for Dan and the organisation and the prospective rewards it will deliver. Not only to investors but science/pharmaceutical development and its ultimate altruistic/therapeutic benefits. Therefore, have no intention of diluting my holding, however, I have no problem if fellow investors wish to do so, hey ho it’s their choice and they must have their reasons.
investor what a load nonsense. Rise last week was on the back of Japan news expectation. Priced at the moment reflects that fact that China deal has completely fallen through ! Hopefully Japan news shortly, great posts by Mars1! Muhunthan Thillai appears to be the real deal and some of the things he is involved in are amazing!
our ex chairman selling is complete rubbish imo.. he will of been sent legal letters about his dismissal and the reasons for it. He was then, and is now. Garnished and in has inside information.this effects him in many legal ways. 1 is he can not by law sell until that info is out in the public domain. This applies to china and all aspects of the company (Japan deal ) CPI is a different beast. they can imo but they are also aware of the facts. I assume any good new chairman or dan for that matter. would be telling all large sh what the pipeline holds and where the sp will be.. So I have seen no large sells, this sort of confirms these points imo
Dan has to release news as soon as its apparent I agree there are background sellers and the share will not rerate until we get positive news and the big investors move in. This is when the market will take the sells without hammering the price
Professor Kaminski from Yale has tweeted Naftali Kaminski @KaminskiMed · Feb 17 Did small airway disease just become a feature of IPF? Read this superb editorial that integrates the two recent papers on loss of small airways in IPF
Its absolutely clear to see what is happening here, cpi and ex ceo are selling, sp went down to 4,5,6 and the selling stopped as a result the sp went up last week, the selling has begun, these sellers want a decent return, they dont want to sell below 6p, it will take months for the sellers to clear and it the meantime any news that arrives the sellers will make sure they put all the stops on a rerate (new floor), if i was dan i would not release any news until the sellers had finished even if it means waiting 12 months that way the sp would be free to rise